» Articles » PMID: 36646720

The Telomerase Activator TA-65 Protects from Cigarette Smoke-induced Small Airway Remodeling in Mice Through Extra-telomeric Effects

Abstract

Small airway remodeling (SAR) is a key phenomenon of airflow obstruction in smokers, leading to chronic obstructive pulmonary disease (COPD). SAR results in an increased thickness of small airway walls, with a combination of peribronchiolar fibrosis with increased fibrous tissue and accumulation of mesenchymal and epithelial cells. SAR pathogenesis is still unclear but recent data suggest that alterations in telomerase activity could represent a possible underlying mechanism of SAR. Our study was dedicated to identify a potential protective role of TA-65, a pharmacological telomerase activator, in a cigarette smoke (CS) model of SAR in mice, and to further precise if extra-telomeric effects of telomerase, involving oxidative stress modulation, could explain it. C57BL/6J mice were daily exposed to air or CS during 4 weeks with or without a concomitant administration of TA-65 starting 7 days before CS exposure. Morphological analyses were performed, and mucus production, myofibroblast differentiation, collagen deposition, as well as transforming growth factor-β1 (TGF-β1) expression in the small airway walls were examined. In addition, the effects of TA-65 treatment on TGF-β expression, fibroblast-to-myofibroblast differentiation, reactive oxygen species (ROS) production and catalase expression and activity were evaluated in primary cultures of pulmonary fibroblasts and/or mouse embryonic fibroblasts in vitro. Exposure to CS during 4 weeks induced SAR in mice, characterized by small airway walls thickening and peribronchiolar fibrosis (increased deposition of collagen, expression of α-SMA in small airway walls), without mucus overproduction. Treatment of mice with TA-65 protected them from CS-induced SAR. This effect was associated with the prevention of CS-induced TGF-β expression in vivo, the blockade of TGF-β-induced myofibroblast differentiation, and the reduction of TGF-β-induced ROS production that correlates with an increase of catalase expression and activity. Our findings demonstrate that telomerase is a critical player of SAR, probably through extra-telomeric anti-oxidant effects, and therefore provide new insights in the understanding and treatment of COPD pathogenesis.

Citing Articles

Unlocking longevity: the role of telomeres and its targeting interventions.

Schellnegger M, Hofmann E, Carnieletto M, Kamolz L Front Aging. 2024; 5:1339317.

PMID: 38333665 PMC: 10850353. DOI: 10.3389/fragi.2024.1339317.

References
1.
Churg A, Marshall C, Sin D, Bolton S, Zhou S, Thain K . Late intervention with a myeloperoxidase inhibitor stops progression of experimental chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011; 185(1):34-43. DOI: 10.1164/rccm.201103-0468OC. View

2.
Churg A, Tai H, Coulthard T, Wang R, Wright J . Cigarette smoke drives small airway remodeling by induction of growth factors in the airway wall. Am J Respir Crit Care Med. 2006; 174(12):1327-34. DOI: 10.1164/rccm.200605-585OC. View

3.
Eapen M, Lu W, Hackett T, Singhera G, Mahmood M, Hardikar A . Increased myofibroblasts in the small airways, and relationship to remodelling and functional changes in smokers and COPD patients: potential role of epithelial-mesenchymal transition. ERJ Open Res. 2021; 7(2). PMC: 8181830. DOI: 10.1183/23120541.00876-2020. View

4.
Rubio M, Ortega M, Peces-Barba G, Escolar J, Verbanck S, Paiva M . N-acetylcysteine prevents cigarette smoke induced small airways alterations in rats. Eur Respir J. 2000; 15(3):505-11. DOI: 10.1034/j.1399-3003.2000.15.13.x. View

5.
Harley C, Liu W, Blasco M, Vera E, Andrews W, Briggs L . A natural product telomerase activator as part of a health maintenance program. Rejuvenation Res. 2010; 14(1):45-56. PMC: 3045570. DOI: 10.1089/rej.2010.1085. View